Life Science Investing Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
Life Science Investing Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
Life Science Investing Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
Finlay Minerals Announces Closing of Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units
